At this moment, these molecules are investigated in several clinical trials for patients with metastatic melanoma alone or in combination with BRAF and/or MEK inhibitors [129] (NCT02065063, NCT01781572). The gene discussed is MAP2K7; the disease is metastatic melanoma.